|
The Lotronex Action Group seeks immediate access to the medicine Lotronex
(alosetron hydrochloride) while avenues for continued marketing are explored between GlaxoSmithKline and the Food and Drug Administration. Moreover, the LAG
ultimately seeks permanent access and safe distribution of the medicine to those
diagnosed with IBS-Diarrhea.
The Lotronex Action Group submitted a petition to the Food and Drug Administration on March 21, 2001.
The Lotronex Action Group received an interim response from the Food and Drug Administation on October 3, 2001.
Main
| About Us | Petition
| LAG News
Press
| Links
| Industry Contacts
|
